Plain-English translation of NCT06099106 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Read our Atrial Fibrillation research guide βThis study doesn't follow the usual testing phases β it may be an observational study or a different type of research.
This trial is testing a new device called the ENDOMATIC SEPIOLA Left Atrial Appendage Closure Device. This device is implanted into your heart through a minimally invasive procedure to seal off a small pouch in your heart that can form blood clots when you have atrial fibrillation (irregular heartbeat). The device is designed to help prevent strokes in people who cannot safely take blood-thinning medications long-term.
People with atrial fibrillation are at high risk of stroke because their irregular heartbeat can allow blood clots to form. While blood thinners are typically prescribed to prevent this, some patients cannot tolerate them or have reasons to avoid long-term treatment. This trial exists to evaluate whether this new implanted device can safely prevent strokes as an alternative to blood thinners.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
If you enroll, you will undergo a minimally invasive procedure to have the device implanted into your heart. You will be monitored during the procedure and through hospital discharge. After that, you will have follow-up visits at 45 days, 6 months, and 12 months after the procedure to ensure the device is working properly and check for any side effects.
AI-generated summary from trial data Β· Jun 28, 2026 Β· Not medical advice
Georgia
Lithuania
Poland
Uzbekistan